EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report

Reyad Dada, Refaei Belal Ibrahim

Clinical Case Reports · 2026-04 · 14 (4)

DOI: 10.1002/ccr3.72234 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 30.03.2026. Verfasst von Reyad Dada und 1 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Orphan Biovitrum.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loncastuximab tesirine may offer a feasible, well‐tolerated option for frail, heavily pretreated patients with relapsed/refractory DLBCL and poor performance status when intensive therapies are unsuitable, achieving durable remission with manageable fluid retention through careful monitoring, spironolactone‐based treatment, and dose modification.

Förderung

  • Swedish Orphan Biovitrum

Zitieren

APA

Dada, R., & Ibrahim, R. B. (2026). Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report. Clinical Case Reports, 14(4). https://doi.org/10.1002/ccr3.72234

Vancouver

Dada R, Ibrahim RB. Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report. Clinical Case Reports. 2026;14(4). doi:10.1002/ccr3.72234

BibTeX
@article{Dada2026,
  author = {Dada, Reyad and Ibrahim, Refaei Belal},
  title = {Loncastuximab Tesirine in a Frail, Heavily Pretreated Patient With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Case Report},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {4},
  doi = {10.1002/ccr3.72234}
}
Kostenlos starten →